Merck’s Keytruda went up against chemo in a head-to-head colorectal cancer battle—and won. The immuno-oncology star trumped various chemo regimens at keeping cancer from progressing in previously untreated patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer that had either spread to other parts of the body or couldn’t be surgically removed,… Read More »
When Merck moseyed into the Lone Star State as part of a global IT restructuring, it pitched a robust hiring plan in exchange for nearly $ 7 million in tax breaks and grants. Now, after Merck pulled back the reins on its Austin plans, those incentives have dried up. Merck is walking away from incentive… Read More »
Back in November, Pfizer and Merck KGaA reported that immuno-oncology drug Bavencio had failed a late-stage ovarian cancer trial. And now the companies can make it two. Friday, the partners said they’d scrapped a phase 3 study examining Bavencio in combination with and/or after chemo in previously untreated patients after the drug showed it couldn’t… Read More »
((This NOV 19 story corrects to show Merck is Palantir’s exclusive partner within the JV, not for all of Palantir’s healthcare activities, paragraph 11)) FILE PHOTO: Merck CEO Stefan Oschmann delivers a speech during the celebrations of the 350th anniversary of German pharmaceuticals company Merck at the Merck headquarters in Darmstadt, Germany, May 3 ,2018.… Read More »